This review explores the molecular and cellular mechanisms underlying AS progression, highlights the emerging role of SGLT2 inhibitors as modulators of cardiometabolic remodeling, and discusses the therapeutic implications of integrating SGLT2 inhibition into the management of aortic valve disease. Here, SLC5A2 is linked to aortic stenosis.